Dextran Hydrogel Vascularization via Composite Growth Factor Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current polymeric hydrogels, including dextran-based ones, face challenges in achieving optimal vascular regeneration due to limited tissue or blood vessel ingrowth, despite their potential for delivering angiogenic factors, primarily because of issues with mechanical strength, degradation rates, and crosslinking density, which affect their ability to support neovascularization effectively.
Innovation Solution
The development of dextran-based hydrogels with a reduced degree of substitution and the incorporation of VEGF along with additional angiogenic growth factors like angiopoietin, stromal cell-derived factor, and insulin-like growth factor, combined with poly(ethylene glycol) diacrylate, to enhance mechanical properties and promote efficient tissue and vascular ingrowth through controlled release and crosslinking.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If dextran-based hydrogels are used to deliver angiogenic factors, then growth factor delivery capability is improved, but tissue ingrowth and vascularization are limited due to insufficient mechanical strength and inappropriate degradation rates
Solution Approach 1:
The patent combines dextran-based hydrogels with other biocompatible polymers (such as gelatin, collagen, or synthetic polymers like PEG) to create composite hydrogel systems. This composite approach allows the material to simultaneously provide growth factor delivery capabilities, improved mechanical strength, and controlled degradation rates that support tissue ingrowth and vascularization.
Solution Approach 2:
The patent modifies key parameters of the dextran hydrogel system including crosslinking density, molecular weight of dextran, hydrogel porosity, and degradation rate. By adjusting these parameters, the hydrogel maintains structural integrity while enabling tissue infiltration and supporting angiogenesis through optimized mechanical properties and degradation kinetics.
2Strength
If crosslinking density is increased to improve mechanical strength, then structural integrity is improved, but tissue and blood vessel ingrowth are restricted
Solution Approach 1:
The patent creates hydrogels with spatially varying crosslinking densities or pore sizes, where certain regions have higher crosslinking for structural support while other regions have lower crosslinking to facilitate cell infiltration and tissue ingrowth. This local variation in properties allows simultaneous achievement of mechanical strength and tissue integration.
Solution Approach 2:
The patent designs hydrogels with dynamic or evolving properties where the crosslinking density or pore structure changes over time. Initially, the hydrogel provides structural support with higher crosslinking, then gradually degrades or remodels to allow tissue ingrowth as healing progresses, creating a time-dependent adaptation of mechanical properties.
3Duration of action of stationary object
If degradation rate is accelerated to facilitate tissue replacement, then scaffold replacement is improved, but mechanical support is reduced during critical vascularization period
Solution Approach 1:
The patent designs hydrogels with staged or periodic degradation profiles where degradation occurs in distinct phases. During the early critical period, the hydrogel maintains structural integrity and provides mechanical support. After this period, degradation accelerates to facilitate tissue replacement and scaffold removal, creating a time-dependent degradation pattern that matches the healing timeline.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These hydrogels demonstrate improved mechanical strength, enhanced swelling capacity, and sustained release of growth factors, leading to increased tissue ingrowth and functional vascularization, facilitating therapeutic vascular regeneration and wound healing.
Implementation Method 1
these porous hydrogel scaffolds permit circulating cells to infiltrate into them to degrade them, thereby releasing entrapped growth factors (GFs) and facilitating neovascularization
Implementation Method 2
dextran can be biodegraded by dextranase, which exists in mammalian (including human) tissues
Implementation Method 3
the hydrogel scaffold should have enough mechanical strength to maintain the integrity of its porous structure during the vascularization process
Data Source
AI summary
Slow vascularization of functional blood limits the transplantation of tissue constructs and the recovery of ischemic and wounded tissues. Blood vessel ingrowth into polysaccharide-based hydrogel scaffolds remains a challenge. A synergistic effect of multiple angiogenic GFs was established; the co-encapsulation of VEGF plus other growth factors induced more and larger blood vessels than any individual GF, while the combination of all GFs dramatically increased the size and number of newly formed functional vessels. Rapid, efficient, and functional neovascularization may be achieved.